| abstract |
The invention relates to new annelated indoleketones with an imidazolylalkyl substituent. The new compounds can be represented by formula 2n wherein n-R₁ is alkyl or alkoxy having 1-4 C-atoms, hydroxy, halogen, trifluoromethyl, a group R₅R₆N or R₅R₆-N-CO, wherein R₅ and R₆ are hydrogen or alkyl having 1-4 C-atoms or wherein R₅R₆N is a saturated 5-6 ring, and n has the value 0, 1 or 2; n-A is a group of formulae 3, 4 or 5n wherein one of the groups R₂, R₃ and R₄ is hydrogen, alkyl having 1-4 C-atoms, cycloalkyl having 3-6 C-atoms or alkenyl having 2-4 C-atoms and the two other groups, independently of each other, are hydrogen or alkyl having 1-4 C-atoms, n- p has the value 0-3 and q has the value 2-5. n It has been found that these new compounds and farmaceutically acceptable acid addition salts thereof have a good antagonistic activity of "neuronal" 5-hydroxytryptamine(5- HT) receptors. The activity is considerably prolonged in view of related known compounds. Moreover, the present compound have a lower toxicity. |